Asset profile
SHR-6934
Biologic (subtype unspecified)
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 60 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-6934: this drug | Phase 1 | Biologic (subtype unspecified) | — | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) | ||
| Ivabradine (Corlanor) | Approved | Small molecule | If (funny) channel | ||
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Sotagliflozin (Inpefa) | Approved | Small molecule | SGLT1/2 (dual) | ||
| Tolvaptan (Samsca / Jinarc) | Approved | Small molecule | Vasopressin V2 receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.